Perrigo Company plc Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent
Perrigo Company plc (PRGO) reported Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent of $1.00 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 · last filed 2026-08-05
- Perrigo Company plc other comprehensive income (loss), tax, portion attributable to parent for the quarter ending 2026-06-27 was $1.00M.
- Perrigo Company plc other comprehensive income (loss), tax, portion attributable to parent for the quarter ending 2026-03-28 was $0.00.
- Perrigo Company plc other comprehensive income (loss), tax, portion attributable to parent for the quarter ending 2025-12-31 was $59.50M, a 31.64% increase year-over-year.
- Perrigo Company plc other comprehensive income (loss), tax, portion attributable to parent for the quarter ending 2025-09-27 was -$400.00K.
- Perrigo Company plc other comprehensive income (loss), tax, portion attributable to parent for fiscal 2025 was -$19.40M, a 159.15% decline from fiscal 2024.
- Perrigo Company plc other comprehensive income (loss), tax, portion attributable to parent for fiscal 2024 was $32.80M.
- Perrigo Company plc other comprehensive income (loss), tax, portion attributable to parent for fiscal 2023 was -$25.00M, a 270.07% decline from fiscal 2022.
- Perrigo Company plc other comprehensive income (loss), tax, portion attributable to parent for fiscal 2022 was $14.70M.
| Period end | Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-27 | $1.00M 10-Q · filed 2026-08-05 | $1.00M 10-Q · filed 2026-08-05 | $60.50M derived: sum of 3 quarters · filed 2026-08-05 | $60.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $0.00 10-Q · filed 2026-05-06 | $59.50M derived: sum of 2 quarters · filed 2026-05-06 | $59.10M derived: sum of 3 quarters · filed 2026-05-06 | $3.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $59.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $59.10M derived: sum of 2 quarters · filed 2026-02-26 | $3.20M derived: sum of 3 quarters · filed 2026-08-05 | -$19.40M 10-K · filed 2026-02-26 |
| 2025-09-27 | -$400.00K 10-Q · filed 2025-11-05 | -$56.30M derived: sum of 2 quarters · filed 2026-08-05 | -$78.90M 10-Q · filed 2025-11-05 | -$33.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | -$55.90M 10-Q · filed 2026-08-05 | -$78.50M 10-Q · filed 2026-08-05 | -$33.30M derived: sum of 3 quarters · filed 2026-08-05 | -$61.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | -$22.60M 10-Q · filed 2026-05-06 | $22.60M derived: sum of 2 quarters · filed 2026-05-06 | -$5.10M derived: sum of 3 quarters · filed 2026-05-06 | -$5.50M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $45.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.50M derived: sum of 2 quarters · filed 2026-02-26 | $17.10M derived: sum of 3 quarters · filed 2026-02-26 | $32.80M 10-K · filed 2026-02-26 |
| 2024-09-28 | -$27.70M 10-Q · filed 2025-11-05 | -$28.10M derived: sum of 2 quarters · filed 2025-11-05 | -$12.40M 10-Q · filed 2025-11-05 | |
| 2024-06-29 | -$400.00K 10-Q · filed 2025-08-06 | $15.30M 10-Q · filed 2025-08-06 | ||
| 2024-03-30 | $15.70M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$25.00M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $14.70M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |